EO
EOLS.US Evolus Inc
- Market cap
- USD 461M
- P/E
- -
- P/B
- 53.71x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is EOLS.US undervalued?
Graham numberThe Graham number of Evolus Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Evolus Inc fundamental analysis
No fundamental analysis for Evolus Inc yet.
Evolus Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Evolus Inc
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and e…
Full company profileEvolus Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Evolus Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 34.9M | 56.5M | 99.7M | 149M | 202M | 266M | 297M | 314M |
| Gross Profit | -326K | -218K | 0.00 | 26.9M | 38.2M | 56.1M | 89.8M | 141M | 182M | 193M | 207M |
| Operating Income | -20.0M | -11.7M | -46.1M | -98.9M | -153M | -44.4M | -65.3M | -49.2M | -34.4M | -37.6M | -24.3M |
| EBITDA | -19.6M | -11.5M | -45.9M | -92.1M | -145M | -39.1M | -53.1M | -41.8M | -25.0M | -22.5M | -15.3M |
| Net Income | -20.1M | -4.48M | -46.9M | -90.0M | -163M | -46.8M | -74.4M | -61.7M | -50.4M | -51.6M | -41.7M |
| EPS | -1.08 | -0.19 | -1.92 | -3.19 | -4.83 | -0.94 | -1.33 | -1.08 | -0.81 | -0.80 | -0.63 |
| Balance Sheet | |||||||||||
| Total Assets | 77.5M | 152M | 172M | 240M | 209M | 257M | 178M | 189M | 233M | 226M | 284M |
| Total Liabilities | 84.6M | 228M | 87.5M | 161M | 282M | 176M | 159M | 210M | 227M | 249M | 322M |
| Shareholders' Equity | -7.11M | -75.5M | 84.4M | 79.5M | -73.0M | 81.9M | 18.5M | -20.7M | 5.52M | -23.1M | -37.8M |
| Cash & Short-term Investments | 187K | 0.00 | 93.2M | 130M | 108M | 146M | 53.9M | 62.8M | 87.0M | 53.8M | 41.7M |
| Total Debt | 59.8M | 211M | 16.9M | 96.5M | 138M | 74.7M | 74.4M | 127M | 130M | 155M | 166M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -13.3M | -13.0M | -25.7M | -93.4M | -57.9M | -33.4M | -84.9M | -34.0M | -18.0M | -42.3M | -20.6M |
| Capital Expenditure | 9.00K | 9.00K | 9.00K | 4.57M | 3.14M | 970K | 2.94M | 1.63M | 1.47M | 8.45M | 3.35M |
| Free Cash Flow | -13.3M | -13.0M | -25.7M | -98.0M | -61.0M | -34.4M | -87.9M | -35.6M | -19.5M | -50.7M | -24.0M |
| Ratios | |||||||||||
| ROE | - | - | -55.5% | -113.3% | - | -57.2% | -402.2% | - | -913.1% | - | - |
| ROA | -25.9% | -2.9% | -27.3% | -37.4% | -78.0% | -18.2% | -41.8% | -32.6% | -21.7% | -22.9% | -14.7% |
| Net Profit Margin | - | - | - | -257.8% | -288.3% | -47.0% | -50.1% | -30.5% | -18.9% | -17.4% | -13.3% |
| Debt to Equity | - | - | 0.20x | 1.22x | - | 0.91x | 4.02x | - | 23.54x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Evolus Inc dividends
Evolus Inc has not paid dividends in the last 9 fiscal years.
Who owns Evolus Inc
- Insiders 11.22%
- Institutions 80.74%
- Public & others 8.04%
- Shares outstanding 66.2M
- Free float 48.3M
Top funds holding EOLS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.54M | 2.33% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.50M | 2.27% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 652K | 0.99% | +1.00% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 546K | 0.83% | -0.38% | Oct 2026 |
| State Street® SPDR® S&P® PhrmctlsETF | 419K | 0.63% | +2.88% | Oct 2026 |
| Vanguard Russell 2000 ETF | 345K | 0.52% | +1.01% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 308K | 0.46% | +0.24% | Oct 2026 |
| Fidelity Extended Market Index | 283K | 0.43% | -14.87% | Sep 2026 |
| iShares US Pharmaceuticals ETF | 199K | 0.30% | +0.33% | Oct 2026 |
| iShares Micro-Cap ETF | 180K | 0.27% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 144K | 0.22% | 0.00% | Sep 2026 |
| Vanguard Health Care ETF | 143K | 0.22% | +0.11% | Sep 2026 |
| Fidelity Total Market Index | 125K | 0.19% | -0.05% | Sep 2026 |
| Stt Strt SPDR® Russell2000 US SmCapETF | 120K | 0.18% | -6.50% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 111K | 0.17% | +6.48% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 106K | 0.16% | +174.85% | Aug 2026 |
| Goldman Sachs ActiveBeta® US SmCp Eq ETF | 103K | 0.16% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 101K | 0.15% | 0.00% | Sep 2026 |
| Nuveen Small Cap Blend Idx R6 | 79.2K | 0.12% | 0.00% | Aug 2026 |
| Vanguard US Momentum Factor ETF | 78.5K | 0.12% | 0.00% | Sep 2026 |
Top institutions holding EOLS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 11.2M | 16.96% | +75.70% | Jun 2026 |
| BlackRock Inc | 4.84M | 7.33% | +12.83% | Jun 2026 |
| BRAIDWELL LP | 3.16M | 4.78% | +1.61% | Jun 2026 |
| Frazier Life Sciences Management, L.P. | 2.63M | 3.98% | 0.00% | Jun 2026 |
| Perceptive Advisors LLC | 2.46M | 3.72% | +91.11% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.36M | 3.58% | -4.35% | Jun 2026 |
| Assenagon Asset Management SA | 1.82M | 2.75% | +203.67% | Jun 2026 |
| Millennium Management LLC | 1.79M | 2.71% | +22.36% | Jun 2026 |
| State Street Corp | 1.70M | 2.57% | +28.51% | Jun 2026 |
| Geode Capital Management, LLC | 1.61M | 2.44% | +16.44% | Jun 2026 |
| Stonepine Capital Management Llc | 1.59M | 2.41% | -9.60% | Jun 2026 |
| Point72 Asset Management, L.P. | 1.51M | 2.28% | 0.00% | Jun 2026 |
| Pinnacle Associates Inc | 1.49M | 2.25% | +28.33% | Jun 2026 |
| Armistice Capital, LLC | 1.44M | 2.17% | +2.87% | Jun 2026 |
| Rice Hall James & Associates, LLC | 1.29M | 1.95% | +2.79% | Jun 2026 |
| AWH Capital, L.P. | 1.25M | 1.89% | +100.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.22M | 1.85% | +12.24% | Jun 2026 |
| Soleus Capital Management, L.P. | 822K | 1.25% | -63.37% | Jun 2026 |
| Soviero Asset Management, LP | 770K | 1.17% | +13.17% | Jun 2026 |
| UBS Group AG | 753K | 1.14% | -0.03% | Jun 2026 |
Evolus Inc company profile
- Company name
- Evolus Inc
- Ticker
- EOLS.US
- Exchange
- USA Stocks
- Listed since
- Feb 8, 2018
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 365
- Fiscal year end
- December
- Address
- 520 Newport Center Drive, Newport Beach, CA, United States, 92660
- Phone
- 949 284 4555
- Website
- evolus.com
About Evolus Inc
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Evolus Inc management
7- Mr. David MoatazediPresident, CEO & Director · born 1978
- Ms. Tatjana MitchellChief Financial Officer
- Dr. Rui Avelar C.CFP, Dip.SportMed, M.D.Chief Medical Officer and Head of Research & Development · born 1962
- Mr. Nareg SagherianHead of Global Investor Relations & Corporate Communications
- Mr. Kurt KnabSenior Vice President of Sales
- Ms. Jessica NovakSenior Vice President of Human Resources
- Mr. Jeffrey J. PlumerCorporate Secretary